Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies.

antifungal candidemia de-escalation invasive candidiasis outcome

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 16 03 2021
accepted: 13 05 2021
entrez: 9 6 2021
pubmed: 10 6 2021
medline: 10 6 2021
Statut: epublish

Résumé

There are no clear criteria for antifungal de-escalation after initial empirical treatments. We hypothesized that early de-escalation (ED) (within 5 days) to fluconazole is safe in fluconazole-susceptible candidemia with controlled source of infection. This is a multicenter post hoc study that included consecutive patients from 3 prospective candidemia cohorts (2007-2016). The impact of ED and factors associated with mortality were assessed. Of 1023 candidemia episodes, 235 met inclusion criteria. Of these, 54 (23%) were classified as the ED group and 181 (77%) were classified as the non-ED group. ED was more common in catheter-related candidemia (51.9% vs 31.5%; Early de-escalation is a safe strategy in patients with candidemia caused by fluconazole-susceptible strains with controlled source of bloodstream infection and hemodynamic stability. These results are important to apply antifungal stewardship strategies.

Sections du résumé

BACKGROUND BACKGROUND
There are no clear criteria for antifungal de-escalation after initial empirical treatments. We hypothesized that early de-escalation (ED) (within 5 days) to fluconazole is safe in fluconazole-susceptible candidemia with controlled source of infection.
METHODS METHODS
This is a multicenter post hoc study that included consecutive patients from 3 prospective candidemia cohorts (2007-2016). The impact of ED and factors associated with mortality were assessed.
RESULTS RESULTS
Of 1023 candidemia episodes, 235 met inclusion criteria. Of these, 54 (23%) were classified as the ED group and 181 (77%) were classified as the non-ED group. ED was more common in catheter-related candidemia (51.9% vs 31.5%;
CONCLUSIONS CONCLUSIONS
Early de-escalation is a safe strategy in patients with candidemia caused by fluconazole-susceptible strains with controlled source of bloodstream infection and hemodynamic stability. These results are important to apply antifungal stewardship strategies.

Identifiants

pubmed: 34104670
doi: 10.1093/ofid/ofab250
pii: ofab250
pmc: PMC8180243
doi:

Types de publication

Journal Article

Langues

eng

Pagination

ofab250

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Références

Clin Microbiol Infect. 2015 Jul;21(7):684.e1-9
pubmed: 25765773
Intensive Care Med. 2015 Nov;41(11):1931-40
pubmed: 26370688
BMC Infect Dis. 2011 Sep 30;11:261
pubmed: 21961941
Clin Infect Dis. 2003 Nov 1;37(9):1172-7
pubmed: 14557960
Crit Care Med. 2018 Mar;46(3):384-393
pubmed: 29189345
Crit Care Med. 2011 Apr;39(4):665-70
pubmed: 21169817
J Med Econ. 2013 Nov;16(11):1344-56
pubmed: 24003830
Antimicrob Agents Chemother. 2008 Nov;52(11):4175-7
pubmed: 18809944
Clin Infect Dis. 2016 Feb 15;62(4):e1-50
pubmed: 26679628
Clin Microbiol Infect. 2016 Feb;22(2):181-188
pubmed: 26460064
Mycoses. 2016 Mar;59(3):179-85
pubmed: 26707572
Antimicrob Agents Chemother. 2014;58(3):1529-37
pubmed: 24366741
Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37
pubmed: 23137135
Int J Clin Pract. 2014 Jan;68(1):20-7
pubmed: 24341299
BMC Infect Dis. 2014 Feb 21;14:97
pubmed: 24559321
Antimicrob Agents Chemother. 2011 Feb;55(2):561-6
pubmed: 21115790
Intensive Care Med. 2003 Apr;29(4):530-8
pubmed: 12664219
Clin Infect Dis. 2019 May 30;68(12):1981-1989
pubmed: 30289478
Clin Infect Dis. 2009 Jun 15;48(12):1695-703
pubmed: 19441981

Auteurs

E Moreno-García (E)

Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.

P Puerta-Alcalde (P)

Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.

G Gariup (G)

Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.

M Fernández-Ruiz (M)

Hospital Universitario "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (imas+12), Universidad Complutense, Madrid, Spain.

L E López Cortés (LE)

Unidad de Gestión Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen Macarena, CSIC, Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain.

G Cuervo (G)

Hospital Universitari de Bellvitge, IDIBELL (Institut D'Investigació Biomèdica de Bellvitge), Universitat de Barcelona, Barcelona, Spain.

M Salavert (M)

Hospital Universitari i Politecnic "La Fe", Valencia, Spain.

P Merino (P)

Hospital Universitario Clínico "San Carlos", Madrid, Spain.

M Machado (M)

Hospital General Universitario Gregorio Marañón e Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain.

J Guinea (J)

Hospital General Universitario Gregorio Marañón e Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain.

J García-Rodríguez (J)

Hospital Universitario "La Paz", Madrid, Spain.

J Garnacho-Montero (J)

Unidad Clínica de Cuidados Intensivos, Hospital Universitario "Virgen Macarena", Sevilla, Spain.

C Cardozo (C)

Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.

J Peman (J)

Hospital Universitari i Politecnic "La Fe", Valencia, Spain.

M Montejo (M)

Hospital Universitario "Cruces", Bilbao, Spain.

J Fortún (J)

Hospital Universitario "Ramón y Cajal", Madrid, Spain.

B Almirante (B)

Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

C Castro (C)

Hospital Universitario de Valme, Sevilla, Spain.

J Rodríguez-Baño (J)

Unidad de Gestión Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen Macarena, CSIC, Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain.

J M Aguado (JM)

Hospital Universitario "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (imas+12), Universidad Complutense, Madrid, Spain.

J A Martínez (JA)

Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.

J Carratalà (J)

Hospital Universitari de Bellvitge, IDIBELL (Institut D'Investigació Biomèdica de Bellvitge), Universitat de Barcelona, Barcelona, Spain.

A Soriano (A)

Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.

C Garcia-Vidal (C)

Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.

Classifications MeSH